GlaxoSmithKline PLC (GSK.L)
1,670.00GBp
12:11pm EDT
11.50p (+0.69%)
1,658.50p
1,662.50p
1,673.00p
1,649.50p
5,480,970
7,631,653
1,816.00p
1,314.00p
GSK.L
About
Overall
| Beta: | 0.48 |
| Market Cap (Mil.): | £81,485.68 |
| Shares Outstanding (Mil.): | 4,913.22 |
| Dividend: | 18.00 |
| Yield (%): | 4.52 |
Financials
| GSK.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 19.63 | 32.01 | 32.18 |
| EPS (TTM): | 0.85 | -- | -- |
| ROI: | 15.87 | 19.61 | 18.91 |
| ROE: | 54.57 | 20.45 | 19.87 |
Chinese police investigating local GlaxoSmithKline staff: report
SHANGHAI - High-level Chinese staff at British drugmaker GlaxoSmithKline Plc are being investigated by police in the south-central Chinese city of Changsha on suspicion of unspecified economic crimes, the official Xinhua News Agency reported.
PRESS DIGEST - British Business - July 1
July 1 - The following are the top stories on the business pages of British newspapers. Reuters has not verified these stories and does not vouch for their accuracy.
Blackstone, Lion Capital to bid for GSK's Lucozade, Ribena: report
- Private equity firms Blackstone and Lion Capital have teamed up to make a formal bid worth more than a billion pounds for Lucozade and Ribena, the two soft drink brands put up for sale by drugmaker GlaxoSmithKline , Sky News reported on Sunday.
Blackstone, Lion Capital to bid for GSK's Lucozade, Ribena - report
June 30 - Private equity firms Blackstone and Lion Capital have teamed up to make a formal bid worth more than a billion pounds for Lucozade and Ribena, the two soft drink brands put up for sale by drugmaker GlaxoSmithKline , Sky News reported on Sunday.
GSK muscular dystrophy drug gets "breakthrough" status
LONDON, June 27 - GlaxoSmithKline said on Thursday U.S. regulators have given breakthrough therapy status for its investigational compound drisapersen for the potential treatment of patients with duchenne muscular dystrophy (DMD).
New drugs allow GSK disposals to 'far exceed' acquisitions
LONDON - Disposals are trumping acquisitions as GlaxoSmithKline slims down ready for a wave of its new medicines to reach the market.
New GSK diabetes drug works, but faces tough competition
LONDON - GlaxoSmithKline's experimental once-weekly diabetes drug albiglutide was effective in late-stage clinical trials, but the medicine may struggle to differentiate itself in an increasingly competitive market.
New GSK diabetes drug works, but faces tough competition
LONDON, June 24 - GlaxoSmithKline's experimental once-weekly diabetes drug albiglutide was effective in late-stage clinical trials, but the medicine may struggle to differentiate itself in an increasingly competitive market.
GSK links with French venture firm to target rare diseases
LONDON - GlaxoSmithKline is investing 17.5 million euros ($23.5 million) in a new venture fund to invest in drugs for rare diseases, underscoring the growing role of big drugmakers in backing start-up companies.
GSK links with French venture firm to target rare diseases
LONDON, June 20 - GlaxoSmithKline is investing 17.5 million euros ($23.5 million) in a new venture fund to invest in drugs for rare diseases, underscoring the growing role of big drugmakers in backing start-up companies.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Pechala's Reports
|
$15.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
